PBAC's latest decision on Strontium ranelate: Not recommended (2015). Considered for Treatment of severe established osteoporosis in patients unable to use other osteoporosis medications and without cardiovascular contraindications.
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
7
first 2005
Submissions
7
2005 → 2015
Eligible population
Patients with severe established osteoporosis unable to use other osteoporosis medications and without cardiovascular contraindications
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
Other
Primary endpoint
Other
Comparator
other osteoporosis medications
Economic model
CUA
ICER note
PBAC set threshold of <$15,000–$45,000/QALY for listing. Sponsor's offered price resulted in ICER significantly higher than this threshold. Specific ICER values in submission are redacted (marked with '''''').
ICER (historical)
$15k/QALY–$45k/QALY across 2 submissions (2006–2015) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Why PBAC said no
Reasons cited in the latest PSD: Sponsor's offered price did not achieve the cost-effectiveness threshold of <$15,000–$45,000/QALY set by PBAC in July 2015; no new evidence provided to support an ICER greater than this threshold
Submission history
Jul 2005: Recommended with restriction · Authority Required
Nov 2006: Not recommended · Authority Required — ICER $45k/QALY
Jul 2007: Recommended with restriction · Authority Required
Jul 2012: Recommended with restriction · Authority Required (STREAMLINED)
Jul 2014: Recommended with restriction · Authority Required
Jul 2015: Recommended with restriction · Restricted
Nov 2015: Not recommended · Restricted — ICER $45k/QALY